Cargando…
Is De-escalated Bisphosphonates Therapy a Suitable Alternative to Standard Dosing in Malignant Tumor Patients With Bone Metastases: A Systematic Review and Meta-Analysis
Background: Previous studies have preliminarily identified the non-inferior efficacy for reducing skeletal-related event (SRE) rates between de-escalated (Q12w) and standard (Q3-4w) bone-targeting agents therapy in malignant tumor patients with bone metastases. In this study, we aim to make further...
Autores principales: | Luo, Qiuhua, Men, Peng, Liu, Zhiyong, Zhai, Suodi, Jiang, Mingyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702312/ https://www.ncbi.nlm.nih.gov/pubmed/31475116 http://dx.doi.org/10.3389/fonc.2019.00774 |
Ejemplares similares
-
Low radiotherapy dose is suitable for brain metastases in SCLC compared with high dose
por: Xu, Liming, et al.
Publicado: (2023) -
Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases
por: Addison, Christina L, et al.
Publicado: (2014) -
Bisphosphonates and bone metastases.
por: Morton, A. R., et al.
Publicado: (1988) -
Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis
por: Yang, Wenhan, et al.
Publicado: (2020) -
Feasibility of Dose Escalation in Patients With Intracranial Pediatric Ependymoma
por: Tensaouti, Fatima, et al.
Publicado: (2019)